Concepts (129)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sarcoma, Kaposi | 12 | 2025 | 123 | 2.600 |
Why?
|
| HIV Infections | 14 | 2023 | 1949 | 1.270 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2020 | 261 | 0.930 |
Why?
|
| Neoplasms | 7 | 2022 | 2855 | 0.750 |
Why?
|
| Hematology | 3 | 2018 | 40 | 0.740 |
Why?
|
| Malawi | 11 | 2025 | 310 | 0.670 |
Why?
|
| Anemia, Neonatal | 1 | 2020 | 8 | 0.650 |
Why?
|
| Anemia, Hemolytic | 1 | 2020 | 31 | 0.650 |
Why?
|
| Phototherapy | 1 | 2020 | 36 | 0.640 |
Why?
|
| Erythrocyte Transfusion | 1 | 2020 | 136 | 0.590 |
Why?
|
| Hemoglobins | 1 | 2020 | 311 | 0.590 |
Why?
|
| Antineoplastic Agents | 4 | 2020 | 1758 | 0.570 |
Why?
|
| Developing Countries | 3 | 2017 | 298 | 0.550 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2025 | 1302 | 0.540 |
Why?
|
| Medical Oncology | 2 | 2018 | 229 | 0.540 |
Why?
|
| Botswana | 5 | 2020 | 73 | 0.430 |
Why?
|
| Herpesvirus 8, Human | 4 | 2023 | 46 | 0.430 |
Why?
|
| Drugs, Essential | 1 | 2013 | 7 | 0.400 |
Why?
|
| Pediatrics | 3 | 2018 | 1204 | 0.390 |
Why?
|
| Fibrinolysis | 1 | 2010 | 43 | 0.330 |
Why?
|
| Noonan Syndrome | 1 | 2010 | 31 | 0.330 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2010 | 50 | 0.330 |
Why?
|
| Child | 21 | 2025 | 25094 | 0.330 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2010 | 112 | 0.310 |
Why?
|
| Health Services Accessibility | 2 | 2017 | 661 | 0.280 |
Why?
|
| Child, Preschool | 11 | 2025 | 14343 | 0.270 |
Why?
|
| Vincristine | 2 | 2020 | 190 | 0.270 |
Why?
|
| Hemorrhage | 1 | 2010 | 492 | 0.260 |
Why?
|
| HIV-1 | 2 | 2018 | 469 | 0.210 |
Why?
|
| Socioeconomic Factors | 2 | 2017 | 872 | 0.200 |
Why?
|
| Anemia | 2 | 2020 | 339 | 0.200 |
Why?
|
| Adolescent | 10 | 2025 | 19994 | 0.200 |
Why?
|
| Humans | 28 | 2025 | 126848 | 0.200 |
Why?
|
| Female | 15 | 2025 | 68387 | 0.190 |
Why?
|
| Infant | 9 | 2025 | 12765 | 0.190 |
Why?
|
| Retrospective Studies | 10 | 2025 | 16986 | 0.190 |
Why?
|
| Wilms Tumor | 1 | 2023 | 116 | 0.180 |
Why?
|
| Male | 15 | 2025 | 62565 | 0.180 |
Why?
|
| Interleukin-6 | 2 | 2019 | 406 | 0.160 |
Why?
|
| Malnutrition | 1 | 2022 | 150 | 0.160 |
Why?
|
| Bleomycin | 2 | 2020 | 110 | 0.160 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2020 | 62 | 0.160 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2020 | 130 | 0.150 |
Why?
|
| Doxorubicin | 1 | 2020 | 286 | 0.150 |
Why?
|
| Infant, Newborn | 4 | 2020 | 8358 | 0.150 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2025 | 1233 | 0.150 |
Why?
|
| Kidney Neoplasms | 1 | 2023 | 436 | 0.140 |
Why?
|
| Neoplasm Staging | 2 | 2023 | 1281 | 0.140 |
Why?
|
| Delayed Diagnosis | 1 | 2020 | 128 | 0.140 |
Why?
|
| Paclitaxel | 2 | 2020 | 128 | 0.140 |
Why?
|
| Hematologic Diseases | 1 | 2018 | 75 | 0.140 |
Why?
|
| Anti-HIV Agents | 2 | 2020 | 344 | 0.140 |
Why?
|
| Herpesviridae Infections | 1 | 2018 | 137 | 0.130 |
Why?
|
| Viral Load | 1 | 2018 | 398 | 0.130 |
Why?
|
| Vitamin B 12 | 1 | 2016 | 57 | 0.120 |
Why?
|
| Vitamin B 12 Deficiency | 1 | 2016 | 44 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2020 | 1047 | 0.120 |
Why?
|
| Risk | 1 | 2017 | 730 | 0.120 |
Why?
|
| Remission Induction | 1 | 2016 | 298 | 0.120 |
Why?
|
| Hematologic Neoplasms | 1 | 2018 | 294 | 0.120 |
Why?
|
| Critical Care | 1 | 2020 | 666 | 0.110 |
Why?
|
| Databases, Factual | 1 | 2020 | 1193 | 0.110 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 152 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2015 | 217 | 0.100 |
Why?
|
| Anti-Retroviral Agents | 1 | 2015 | 144 | 0.100 |
Why?
|
| Cytokines | 1 | 2019 | 1318 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2014 | 101 | 0.100 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2013 | 18 | 0.100 |
Why?
|
| Mouth Neoplasms | 1 | 2013 | 93 | 0.090 |
Why?
|
| Thrombocytopenia | 1 | 2013 | 222 | 0.090 |
Why?
|
| Lymph Nodes | 1 | 2013 | 373 | 0.090 |
Why?
|
| Plasminogen | 1 | 2010 | 7 | 0.080 |
Why?
|
| Prothrombin Time | 1 | 2010 | 35 | 0.080 |
Why?
|
| Antithrombin III | 1 | 2010 | 26 | 0.080 |
Why?
|
| Partial Thromboplastin Time | 1 | 2010 | 44 | 0.080 |
Why?
|
| Hemostasis | 1 | 2010 | 72 | 0.080 |
Why?
|
| Prognosis | 2 | 2017 | 4770 | 0.080 |
Why?
|
| Peptide Hydrolases | 1 | 2010 | 133 | 0.080 |
Why?
|
| Epilepsy | 1 | 2015 | 844 | 0.070 |
Why?
|
| Africa South of the Sahara | 2 | 2018 | 114 | 0.070 |
Why?
|
| Adult | 4 | 2023 | 30413 | 0.070 |
Why?
|
| Recurrence | 2 | 2025 | 1406 | 0.060 |
Why?
|
| Survival Rate | 2 | 2025 | 2099 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2006 | 80 | 0.060 |
Why?
|
| Time Factors | 1 | 2016 | 6137 | 0.060 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 880 | 0.060 |
Why?
|
| Imidazoles | 1 | 2006 | 217 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2020 | 6201 | 0.060 |
Why?
|
| Piperazines | 1 | 2006 | 255 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 9660 | 0.050 |
Why?
|
| Nephrectomy | 1 | 2023 | 172 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2006 | 539 | 0.040 |
Why?
|
| Virus Replication | 1 | 2023 | 593 | 0.040 |
Why?
|
| Nutritional Status | 1 | 2022 | 299 | 0.040 |
Why?
|
| Aged | 1 | 2018 | 20331 | 0.040 |
Why?
|
| Apoptosis | 1 | 2006 | 1813 | 0.040 |
Why?
|
| Lymphadenopathy | 1 | 2019 | 31 | 0.040 |
Why?
|
| Patient Admission | 1 | 2020 | 181 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 1220 | 0.040 |
Why?
|
| Capacity Building | 1 | 2018 | 21 | 0.040 |
Why?
|
| Endemic Diseases | 1 | 2018 | 59 | 0.040 |
Why?
|
| Middle Aged | 1 | 2018 | 27695 | 0.040 |
Why?
|
| Virus Activation | 1 | 2018 | 84 | 0.040 |
Why?
|
| Patient Care | 1 | 2018 | 99 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2020 | 494 | 0.030 |
Why?
|
| Asia | 1 | 2017 | 121 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2020 | 558 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 1138 | 0.030 |
Why?
|
| Europe | 1 | 2017 | 363 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2025 | 5113 | 0.030 |
Why?
|
| HIV | 1 | 2017 | 170 | 0.030 |
Why?
|
| Fellowships and Scholarships | 1 | 2018 | 315 | 0.030 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2020 | 475 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 3662 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2018 | 1399 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2593 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2018 | 536 | 0.030 |
Why?
|
| Radiography, Thoracic | 1 | 2014 | 148 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2016 | 613 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 12537 | 0.020 |
Why?
|
| United States | 1 | 2023 | 11310 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2015 | 3317 | 0.020 |
Why?
|
| Pregnancy | 1 | 2020 | 7412 | 0.020 |
Why?
|
| HCT116 Cells | 1 | 2006 | 60 | 0.020 |
Why?
|
| Risk Factors | 1 | 2020 | 10551 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2006 | 232 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2006 | 727 | 0.010 |
Why?
|
| Mice | 1 | 2006 | 17629 | 0.000 |
Why?
|
| Animals | 1 | 2006 | 33194 | 0.000 |
Why?
|